QURE Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

5.66M

+8.4%

-0.926

-38.27%

6.82M

+335.74%

-0.902

+10.12%

7.87M

+50.45%

-0.919

+32.9%

Estimates Revision

The market is revising Downward the revenue expectations for uniQure N.V. (QURE) for FY2025, with the revenue forecasts being adjusted by -0.34% over the past three months. During the same period, the stock price has changed by -60.22%.

Revenue Estimates for FY2025

Revise Downward

-0.34%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-60.22%

In Past 3 Month

12 Analyst Rating

Wall Street analysts forecast QURE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QURE is 62.60 USD with a low forecast of 38.00 USD and a high forecast of 95.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

2 Hold

0 Sell

Strong Buy

Current: 0.000

Low

38.00

Averages

62.60

High

95.00

Current: 0.000

Low

38.00

Averages

62.60

High

95.00

Stifel

Buy

downgrade

$50 -> $40

2025-12-11

Reason

Stifel

Price Target

$50 -> $40

2025-12-11

downgrade

Buy

Reason

Stifel lowered the firm's price target on uniQure to $40 from $50 and keeps a Buy rating on the shares. The firm "refreshed diligence" on many companies within its biotechnology coverage universe and made a number of model, estimate and price target changes in a 2026 look ahead note for the group.

Mizuho

Uy Ear

Outperform

NULL

downgrade

$60 -> $33

2025-12-08

Reason

Mizuho

Uy Ear

Price Target

$60 -> $33

2025-12-08

downgrade

Outperform

NULL

Reason

Mizuho analyst Uy Ear lowered the firm's price target on uniQure to $33 from $60 and keeps an Outperform rating on the shares after lowering the firm's view of the probability of success and pushing out its expected launch year for AMT-130 by one year following the company announcing that the FDA conveyed that data submitted from the Phase I/II studies of AMT-130 for Huntington's disease are currently unlikely to provide the primary evidence to support a Biologics License Application.

Leerink

Outperform

NULL

downgrade

$68 -> $60

2025-11-10

Reason

Leerink

Price Target

$68 -> $60

2025-11-10

downgrade

Outperform

NULL

Reason

Leerink lowered the firm's price target on uniQure to $60 from $68 and keeps an Outperform rating on the shares following quarterly results and earnings call, which was "unsurprisingly" focused on the regulatory path for AMT-130 in Huntington's disease. Leerink acknowledges the "surprise" last week when uniQure sounded the alarm and disclosed that the FDA no longer agreed that the data from the Phase 1/2 studies and prespecified analyses vs. an external control may be adequate to provide primary evidence in support of a BLA submission. On the call today, uniQure emphasized that this FDA reversal does not change their data for AMT-130 in HD that support real and serious disease modification. While this news has made timing of a BLA submission uncertain, the company plans to urgently engage with the FDA to discuss next steps, beginning with the formal meeting minutes.

William Blair

Myles Minter

Outperform -> Market Perform

downgrade

2025-11-05

Reason

William Blair

Myles Minter

Price Target

2025-11-05

downgrade

Outperform -> Market Perform

Reason

William Blair analyst Myles Minter downgraded Biohaven (BHVN) to Market Perform from Outperform. The announcement of a CRL for troriluzole in spinocerebellar ataxia halts not only a near-term source of revenue but also the ability of the company to access $150M in capital through its note purchase agreement with Oberland Capital, the analyst tells investors. Even with a 60% reduction in annual R&D spending, the firm believes Biohaven will need additional capital to continue to fund its pipeline or seek strategic alternatives for its deprioritized pipeline assets, notes the analyst, who is moving to the sidelines to await regulatory clarity given that the FDA has now been restrictive to both uniQure's (QURE) and Biohaven's comparisons to natural history as a regulatory path forward in rare neurological disorders.

William Blair

Sami Corwin

Outperform -> Market Perform

downgrade

2025-11-04

Reason

William Blair

Sami Corwin

Price Target

2025-11-04

downgrade

Outperform -> Market Perform

Reason

William Blair analyst Sami Corwin downgraded uniQure to Market Perform from Outperform.

William Blair

Outperform -> Market Perform

downgrade

2025-11-04

Reason

William Blair

Price Target

2025-11-04

downgrade

Outperform -> Market Perform

Reason

William Blair downgraded uniQure to Market Perform from Outperform without a price target. The company announced that following a recent meeting, it believes the FDA no longer agrees that the data from the Phase I/II trial of AMT-130 in comparison to external controls support an application submission because the statistical analysis plan was not proposed prior to the start of the trial, the analyst tells investors in a research note. The firm views the development as a "significant divergence" from the guidance provided by the agency in November 2024. Blair believes the path forward for AMT-130 is now uncertain.

Valuation Metrics

The current forward P/E ratio for Uniqure NV (QURE.O) is -6.37, compared to its 5-year average forward P/E of -5.46. For a more detailed relative valuation and DCF analysis to assess Uniqure NV 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.46

Current PE

-6.37

Overvalued PE

8.89

Undervalued PE

-19.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.59

Current EV/EBITDA

-8.48

Overvalued EV/EBITDA

1.12

Undervalued EV/EBITDA

-10.31

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

17.09

Current PS

43.65

Overvalued PS

38.23

Undervalued PS

-4.06

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

QURE News & Events

Events Timeline

No data

News

9.0

01-09Benzinga

uniQure's AMT-130 Gene Therapy Under FDA Review, Shares Surge 10.84%

9.0

01-09NASDAQ.COM

uniQure Schedules FDA Meeting for AMT-130 Accelerated Approval Discussion

9.0

01-09Newsfilter

uniQure Schedules FDA Meeting to Discuss Accelerated Approval for AMT-130

People Also Watch

Frequently Asked Questions

What is Uniqure NV (QURE) stock price today?

The current price of QURE is 25.32 USD — it has increased 9.37 % in the last trading day.

What is Uniqure NV (QURE)'s business?

Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

What is the price predicton of QURE Stock?

What is Uniqure NV (QURE)'s revenue for the last quarter?

Uniqure NV revenue for the last quarter amounts to 3.70M USD, increased 61.83 % YoY.

What is Uniqure NV (QURE)'s earnings per share (EPS) for the last quarter?

Uniqure NV. EPS for the last quarter amounts to -1.38 USD, increased 51.65 % YoY.

What changes have occurred in the market's expectations for Uniqure NV (QURE)'s fundamentals?

How many employees does Uniqure NV (QURE). have?

Uniqure NV (QURE) has 209 emplpoyees as of January 10 2026.

What is Uniqure NV (QURE) market cap?

Today QURE has the market capitalization of 1.58B USD.